File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12026-010-8172-z
- Scopus: eid_2-s2.0-79958725758
- PMID: 20717741
- WOS: WOS:000284275400011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Prospects of a novel vaccination strategy for human gamma-herpesviruses
Title | Prospects of a novel vaccination strategy for human gamma-herpesviruses |
---|---|
Authors | |
Keywords | EBV Vaccine Gamma-herpesviruses KSHV MHV-68 |
Issue Date | 2010 |
Citation | Immunologic Research, 2010, v. 48, n. 1-3, p. 122-146 How to Cite? |
Abstract | Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, γHV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine. © Springer Science+Business Media, LLC 2010. |
Persistent Identifier | http://hdl.handle.net/10722/285679 |
ISSN | 2023 Impact Factor: 3.3 2023 SCImago Journal Rankings: 0.870 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wu, Ting Ting | - |
dc.contributor.author | Blackman, Marcia A. | - |
dc.contributor.author | Sun, Ren | - |
dc.date.accessioned | 2020-08-18T04:56:22Z | - |
dc.date.available | 2020-08-18T04:56:22Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | Immunologic Research, 2010, v. 48, n. 1-3, p. 122-146 | - |
dc.identifier.issn | 0257-277X | - |
dc.identifier.uri | http://hdl.handle.net/10722/285679 | - |
dc.description.abstract | Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, γHV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine. © Springer Science+Business Media, LLC 2010. | - |
dc.language | eng | - |
dc.relation.ispartof | Immunologic Research | - |
dc.subject | EBV | - |
dc.subject | Vaccine | - |
dc.subject | Gamma-herpesviruses | - |
dc.subject | KSHV | - |
dc.subject | MHV-68 | - |
dc.title | Prospects of a novel vaccination strategy for human gamma-herpesviruses | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1007/s12026-010-8172-z | - |
dc.identifier.pmid | 20717741 | - |
dc.identifier.pmcid | PMC3931126 | - |
dc.identifier.scopus | eid_2-s2.0-79958725758 | - |
dc.identifier.volume | 48 | - |
dc.identifier.issue | 1-3 | - |
dc.identifier.spage | 122 | - |
dc.identifier.epage | 146 | - |
dc.identifier.eissn | 1559-0755 | - |
dc.identifier.isi | WOS:000284275400011 | - |
dc.identifier.issnl | 0257-277X | - |